StockData
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. (ENVB) stock

ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.42+0.01 (+0.71%)

Close on Nov 18, 2026Market cap $6.36MP/E –Yield –

Enveric Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Enveric Biosciences's free cash flow for the twelve months ending Dec 31, 2023 was -$14.10M. For fiscal 2023 it was -$14.10M.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$14.10M–
FY2022Dec 31, 2022-$17.73M–
FY2021Dec 31, 2021-$11.65M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$1.75M–
Q3 FY2023Sep 30, 2023-$2.74M–
Q2 FY2023Jun 30, 2023-$4.47M–
Q1 FY2023Mar 31, 2023-$5.14M–
Q4 FY2022Dec 31, 2022-$3.47M–
Q3 FY2022Sep 30, 2022-$4.57M–
Q2 FY2022Jun 30, 2022-$4.64M–
Q1 FY2022Mar 31, 2022-$5.05M–

More Enveric Biosciences figures

See a number that looks wrong?